Additional treatment options impact first-line treatment of mRCC: No

What have we learned? Expert perspectives

From clinical trial to clinical practice: Evidence from the real world

Overview of skin cancer treatments, past, present and future

Emerging treatments in CLL: Expert Discussion

Thrombosis in adult patients with chronic ITP

Treatment options in adult chronic idiopathic thrombocytopenic purpura: Introduction

Quality of life and cost advantages of metronomics and drug repurposing

Tackling inequality in access to cancer care and information

Gdf -11 a new target to improve anaemia in thalassemia

Eltrombopag helped reduce bleeding in children with immune thrombocytopenic purpura

Multiple myeloma in the elderly: Expert discussion